Management of Cardiometabolic Complications in Polycystic Ovary Syndrome: Unmet Needs

Overview

Journal FASEB J

Specialties Biology
Physiology

Date 2021 Oct 4

PMID 34606638

Citations 2

Authors

Licy L Yanes Cardozo

Damian G Romero

Affiliations

Soon will be listed here.

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder and the most common cause of androgen excess in reproductive-age women. The heterogeneity of the clinical presentation in PCOS patients suggests the involvement of multiples abnormal physiological pathways. In addition, women with PCOS have a high prevalence of cardiometabolic risk factors. Unfortunately, limited effective evidence-based therapeutic agents are available to treat the cardiometabolic complications in PCOS patients. Insights from recent studies highlight the multiple opportunities to deliver timely effective medical care for women with PCOS. This perspective manuscript aims to highlight the unmet need for effective and safe management of the cardiometabolic complications in PCOS patients.

Citing Articles

Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors.

Pruett J, Romero D, Yanes Cardozo L Front Endocrinol (Lausanne). 2023; 14:951099.

PMID: 36875461 PMC: 9974663. DOI: 10.3389/fendo.2023.951099.

Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: effect of SGLT2 inhibition.

Pruett J, Everman S, Hoang N, Salau F, Taylor L, Edwards K Biol Sex Differ. 2022; 13(1):45.

PMID: 35986388 PMC: 9389812. DOI: 10.1186/s13293-022-00455-x.

References

Zimmerman Y, Eijkemans M, Coelingh Bennink H, Blankenstein M, Fauser B . The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update. 2013; 20(1):76-105. PMC: 3845679. DOI: 10.1093/humupd/dmt038. View

Sanchez-Garrido M, Tena-Sempere M . Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020; 35:100937. PMC: 7115104. DOI: 10.1016/j.molmet.2020.01.001. View

Mehta A, Marso S, Neeland I . Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017; 3(1):3-14. PMC: 5358074. DOI: 10.1002/osp4.84. View

Neyman A, Fuqua J, Eugster E . Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents. J Adolesc Health. 2019; 64(4):544-546. PMC: 6431559. DOI: 10.1016/j.jadohealth.2018.10.296. View

Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z . Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet. 2012; 44(9):1020-5. DOI: 10.1038/ng.2384. View

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W . Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91(11):4237-45. DOI: 10.1210/jc.2006-0178. View

Drucker D, Habener J, Holst J . Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017; 127(12):4217-4227. PMC: 5707151. DOI: 10.1172/JCI97233. View

Gil M, Oliva B, Timoner J, Macia M, Bryant V, de Abajo F . Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol. 2011; 72(6):965-8. PMC: 3244644. DOI: 10.1111/j.1365-2125.2011.04031.x. View

Gambineri A, Pelusi C, Genghini S, Morselli-Labate A, Cacciari M, Pagotto U . Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004; 60(2):241-9. DOI: 10.1111/j.1365-2265.2004.01973.x. View

10.

Giorgetti R, Di Muzio M, Giorgetti A, Girolami D, Borgia L, Tagliabracci A . Flutamide-induced hepatotoxicity: ethical and scientific issues. Eur Rev Med Pharmacol Sci. 2017; 21(1 Suppl):69-77. View

11.

Teede H, Misso M, Costello M, Dokras A, Laven J, Moran L . Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018; 89(3):251-268. PMC: 9052397. DOI: 10.1111/cen.13795. View

12.

Lim S, Norman R, Davies M, Moran L . The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev. 2012; 14(2):95-109. DOI: 10.1111/j.1467-789X.2012.01053.x. View

13.

Zhang B, Wang J, Shen S, Liu J, Sun J, Gu T . Association of Androgen Excess with Glucose Intolerance in Women with Polycystic Ovary Syndrome. Biomed Res Int. 2018; 2018:6869705. PMC: 5863307. DOI: 10.1155/2018/6869705. View

14.

Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba A . The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1998; 83(8):2699-705. DOI: 10.1210/jcem.83.8.5041. View

15.

Azziz R, Sanchez L, Knochenhauer E, Moran C, Lazenby J, Stephens K . Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004; 89(2):453-62. DOI: 10.1210/jc.2003-031122. View

16.

Berni T, Morgan C, Aled Rees D . Women With Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: a Population Study. J Clin Endocrinol Metab. 2021; 106(9):e3369-e3380. PMC: 8372630. DOI: 10.1210/clinem/dgab392. View

17.

Ramezani Tehrani F, Amiri M, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E . Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2019; 36(1):12-23. DOI: 10.1080/09513590.2019.1650337. View

18.

Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F . Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000; 85(1):89-94. DOI: 10.1210/jcem.85.1.6245. View

19.

Amiri M, Kabir A, Nahidi F, Shekofteh M, Ramezani Tehrani F . Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Contracept Reprod Health Care. 2018; 23(1):64-77. DOI: 10.1080/13625187.2018.1435779. View

20.

Morales A, Laughlin G, Butzow T, Maheshwari H, Baumann G, Yen S . Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab. 1996; 81(8):2854-64. DOI: 10.1210/jcem.81.8.8768842. View